Venetoclax Combining Chidamide and Azacitidine (VCA) Regimen Followed by Dicitabine Combined With Liposome Mitoxantrone, Cytarabine, and G-CSF (D-MAG) Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) : A Multicenter, Prospective, Single Arm Clinical Trial

The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

开始日期2022-12-01

申办/合作机构

厦门大学附属第一医院（厦门市第一医院、厦门市红十字会医院、厦门市糖尿病研究所）

[+2]

100 项与重组人粒细胞刺激因子 (石药集团) 相关的临床结果

登录后查看更多信息

100 项与重组人粒细胞刺激因子 (石药集团) 相关的转化医学

登录后查看更多信息

100 项与重组人粒细胞刺激因子 (石药集团) 相关的专利（医药）

登录后查看更多信息

项与重组人粒细胞刺激因子 (石药集团) 相关的文献（医药）

2024-03-01·Int. Journal of Clinical Pharmacology and Therapeutics

Cost-effectiveness analysis of mecapegfilgrastim and recombinant human granulocyte stimulating factor for primary prophylaxis of chemotherapy-induced neutropenia in non-small cell lung cancer

Article

作者: Gu, Yong-Li ; Guan, Xin ; Sun, Zeng-Xian ; Sun, Ying ; Jiang, Dao-Li

OBJECTIVETo evaluate the efficacy, safety, and economics of mecapegfilgrastim and recombinant human granulocyte colony-stimulating factor (rhG-CSF) in the primary prevention of chemotherapy-related neutropenia in non-small cell lung cancer (NSCLC).MATERIALS AND METHODSData from 181 patients with NSCLC who received intermediate risk chemotherapy were collected from the information system of a tertiary hospital in China. Patients were categorized into two groups: those treated with mecapegfilgrastim (n = 91) and those treated with rhG-CSF (n = 90). The clinical efficacy rates of neutropenia prevention were used as effect indicators, and a cost-effectiveness analysis was conducted from the perspective of the Chinese healthcare system. Logistic regression, generalized linear regression, and bootstrap methods were used for sensitivity analyses.RESULTSThere was no statistical difference between the mecapegfilgrastim and rhG-CSF groups in clinical efficacy rates (98.9 vs. 97.8%). However, the total cost in the mecapegfilgrastim group was significantly higher than that in the rhG-CSF group (16,341.6 CNY vs. 14,371.1 CNY, p = 0.03). The cost-minimization analysis shows that mecapegfilgrastim is not cost-effective. The sensitivity analyses confirm that these results are robust.CONCLUSIONCompared with rhG-CSF, mecapegfilgrastim is not a cost-effective strategy for NSCLC patients in neutropenia prevention in China.

2023-08-01·Heliyon

Application of immunomodulatory therapy in a human brucellosis patient with pancytopenia: A case report

作者: Zhao, Leheng ; Dang, Sheng ; Zhai, Jingbo ; Zhang, Guoqing ; Zhang, Shuai ; Wu, Liankui

Brucellosis is a common zoonotic infectious disease with diverse and non-specific clinical manifestations caused by Brucella. Although Brucella can cause damage to multiple systems in the human body, hematological complications are relatively rare. We present a case of a 47-year-old male brucellosis patient with pancytopenia. In May 2018, the patient was diagnosed with brucellosis and recovered after receiving antibiotic treatment (rifampicin 600 mg/day and doxycycline 200 mg/day) for six weeks. However, after three years, the patient experienced a recurring high fever. Brucellosis relapse was confirmed based on the patient's clinical history, Rose Bengal plate agglutination test and standard tube agglutination test results. Routine blood examination revealed a decrease in the whole blood cell count, suggesting bone marrow suppression. Bone marrow aspiration and bacterial culture confirmed the diagnosis of brucellosis with pancytopenia. Antibiotic treatment failed to effectively improve the patient's condition. Therefore, a combination of immunomodulatory and antibiotic treatments was used. The antibiotic regimen included oral rifampicin 600 mg/day, intravenous doxycycline hydrochloride 200 mg/day, and subcutaneous injection of human granulocyte-stimulating factor (0.2 mg/day). Immunomodulatory therapy consisted of 20,000 mg/day intravenous human immunoglobulin (pH 4) for five days and 800 mg/day oral pidotimod liquid for 20 days. As the treatment progressed, the count gradually recovered to normal levels, and the symptoms of bone marrow suppression were alleviated. PCR testing revealed the absence of Brucella DNA in both monocyte and serum samples. Furthermore, negative standard tube agglutination test results were obtained. These findings indicate that the immunomodulatory therapy resulted in a complete clearance of Brucella. Therefore, immunomodulatory therapy could be an effective option in cases of brucellosis with pancytopenia that are unresponsive to conventional antibiotic treatment. Further research and clinical evidence are required to confirm and optimize the use of immunomodulatory therapies in patients with brucellosis.

2023-03-01·Nutrition

Enteral administration of a simulated amniotic fluid in preventing feeding intolerance in very low birthweight neonates: A randomized controlled trial

Article

作者: El-Sheimy, Mohamed S ; Saleh, Ahmed M ; Ismail, Rania I H ; Saleh, Ghada A ; El-Farrash, Rania A

OBJECTIVESFeeding intolerance (FI) is a common finding in preterm neonates. Enteral administration of different forms of amniotic fluid (AF) has been tried for treating FI in high-risk neonates. Simulated amniotic fluid (SAF) is a solution with a similar electrolyte composition to human AF. The aim of this study was to examine whether enteral administration of SAF would improve feeding tolerance in very low birthweight (VLBW) neonates.METHODSForty VLBW neonates were randomized to either SAF or placebo (total daily dose 20 mL/kg/d^-1 divided every 3 h) to their milk for a maximum of 7 d. Neonates with major congenital anomalies, those in whom early feeding was contraindicated, and those treated with parental erythropoietin and/or human granulocyte stimulating factor were excluded. The primary outcome was the total amount of enteral feeds reached by day 7. Secondary outcomes were incidence of FI and necrotizing enterocolitis (NEC). Study intervention was stopped on completing 7 d, reaching enteral feeds of 100 mL/kg/d^-1, or the appearance of any sign of FI or NEC.RESULTSAll neonates tolerated the test solution well. The SAF group reached significantly larger volume and higher calories on days 3 and 7 (P < 0.05 for all). No statistical differences were seen between the two groups in incidence of FI (P = 0.311), NEC (P = 0.429), mortality (P = 0.632), length of stay (P = 0.744), or weight gain on day 10 (P = 0.389). Baseline hematologic parameters showed no statistical differences before or after enteral administration (P > 0.05).CONCLUSIONResults of the present study demonstrated that SAF solution might improve feeding tolerance in VLBW babies without evidence of its systemic absorption. Larger multicenter randomized studies are recommended.

项与重组人粒细胞刺激因子 (石药集团) 相关的新闻（医药）

2024-04-02

·米内网

【关注】大涨166%止血药，杭州药企冲刺国产第2家

精彩内容日前，CDE官网显示，杭州九源基因工程|杭州朱养心药业的马来酸阿伐曲泊帕片以仿制4类报产在审。该产品是一款畅销口服止血药，近年在中国公立医疗机构终端销售规模快速增长，2022年超过6亿元，同比增长166.42%。马来酸阿伐曲泊帕片是口服血小板生成素受体激动剂，能够适用于择期行诊断性操作或者手术的慢性肝病相关血小板减少症的成年患者。2022年中国公立医疗机构终端内服止血药产品TOP10来源：米内网中国公立医疗机构药品终端竞争格局马来酸阿伐曲泊帕片近年在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端销售规模快速增长，2022年超过6亿元，同比增长166.42%，2023年上半年再度增长超过60%，是止血药TOP1产品。马来酸阿伐曲泊帕片报产在审情况来源：米内网中国申报进度（MED）数据库米内网数据显示，马来酸阿伐曲泊帕片仅有2家企业拥有生产批文，2023年11月，南京正大天晴制药拿下首仿和首家过评。此外，山东良福制药、成都倍特药业、四川科伦药业等18家企业以新分类报产在审，获批后视同过评。截至目前，杭州九源基因工程有2款产品报产在审，其中，聚乙二醇化重组人粒细胞刺激因子注射液在2022年中国公立医疗机构终端是40亿元级别的重磅产品。资料来源：CDE官网、米内网数据库注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

100 项与重组人粒细胞刺激因子 (石药集团) 相关的药物交易

登录后查看更多信息